Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients
Table 1
Baseline characteristics.
Parameters
All ()
Responders ()
Nonresponders ()
value
Age—years
74 (36–86)
74 (49–86)
76 (36–83)
0.77
Male gender
22 (69%)
10 (59%)
12 (80%)
0.27
Weight—kg
83 (58–108)
83 (62–100)
82 (58–108)
0.77
Height—cm
173 (145–184)
173 (150–180)
172 (145–184)
0.83
Type of surgery
Coronary artery bypass
13 (41%)
7 (41%)
6 (40%)
1.00
Valve
18 (56%)
10 (59%)
8 (53%)
1.00
Major vascular
9 (28%)
4 (24%)
5 (33%)
0.70
SAPS
37 (18–64)
35 (18–64)
39 (21–63)
0.79
LV ejection fraction—%
57 (35–80)
60 (45–62)
55 (35–80)
0.59
Mechanical ventilation
14 (44%)
7 (41%)
7 (47%)
0.47
Dialysis
7 (22%)
3 (18%)
4 (27%)
0.86
LV: left-ventricular; SAPS: simplified acute physiology score. Results are given as median (minimum–maximum) or numbers (percentages). Groups were compared with Fisher’s exact test or the Mann-Whitney test, as appropriate.
